We are live on ! Find out more
AVM

Arch Venture Management Portfolio holdings

AUM $677M
1-Year Est. Return 322.07%
This Fund
S&P 500
This Quarter Est. Return
+4.72%
1 Year Est. Return
+322.07%
3 Year Est. Return
+208.96%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$164M
AUM Growth
+$9.55M
Cap. Flow
-$9.16M
Cap. Flow %
-5.6%
Top 10 Hldgs %
100%
Holding
8
New
1
Increased
–
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$77.7M

Top Sells

Rank Stock Value
1
EQRX
EQRx, Inc. Common Stock
EQRX
+$80.7M
2
DNLI icon
Denali Therapeutics
DNLI
+$6.19M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVMD icon
1
Revolution Medicines
RVMD
$39.8B
$92.7M 56.72%
+3,233,490
New +$77.7M
VERV
2
DELISTED
Verve Therapeutics
VERV
$28M 17.13%
2,008,809
– –
ERAS icon
3
Erasca
ERAS
$6.66B
$23.5M 14.4%
11,055,554
– –
DNLI icon
4
Denali Therapeutics
DNLI
$3.7B
$8.18M 5%
381,249
-312,500
-45% -$6.19M
GOSS icon
5
Gossamer Bio
GOSS
$68.9M
$7.35M 4.5%
8,055,916
– –
UBX
6
DELISTED
Unity Biotechnology
UBX
$1.94M 1.19%
1,004,817
– –
OMIC
7
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$1.75M 1.07%
126,631
– –
EQRX
8
DELISTED
EQRx, Inc. Common Stock
EQRX
– –
-36,335,375
Closed -$80.7M

Similar funds

NI
Noked Israel Ramat Hasharon, Israel $677M AUM 69.37% 1-Year Est. Return
MMPW
Mitchell McLeod Pugh & Williams Mobile, Alabama $678M AUM 23.02% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
NCM
Noesis Capital Mangement Boca Raton, Florida $676M AUM 34.17% 1-Year Est. Return
TWM
Topsail Wealth Management Charlotte, North Carolina $678M AUM 13.87% 1-Year Est. Return
DLIC
Daido Life Insurance Company Osaka, Japan $678M AUM 16.09% 1-Year Est. Return
REAM
Ripple Effect Asset Management New York $679M AUM 81.6% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Arch Venture Management's Q4 2023 Portfolio in Review

As of Q4 2023, Arch Venture Management held 8 positions worth $164M, up 6.2% from $154M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Arch Venture Management withdrew a net $9.16M in Q4 2023, closing 1 position and reducing 1 holding. Its most notable exit was EQRx, Inc. Common Stock, an estimated $80.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Arch Venture Management opened a new position in Revolution Medicines worth $92.7M.

  • Arch Venture Management's largest Q4 2023 buy was Revolution Medicines: 3,233,490 shares worth $92.7M.
  • Arch Venture Management's biggest Q4 2023 reduction was Denali Therapeutics, cutting an estimated $6.19M.
  • Arch Venture Management fully exited EQRx, Inc. Common Stock in Q4 2023, selling an estimated $80.7M.
  • Arch Venture Management's ten largest holdings make up 100% of its $164M portfolio in Q4 2023.
  • Arch Venture Management opened 1 new position and closed 1 in Q4 2023.
  • Arch Venture Management's portfolio value rose 6.2% quarter-over-quarter to $164M.

Based on Arch Venture Management's 13F filing for Q4 2023, filed 14 Feb 2024.